Skip to main content

Table 2 Clinical characteristics by history of calcinosis

From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis

Risk factor

Descriptive analysis

  

Univariable analysis

Calcinosis

 

OR [95% CI]

p-value

Yes

No

Gender

n (%)

0.0138

  

 Male

33 (39.3)

144 (26.3)

 

1.811 [1.123–2.919]

0.0148

 Female

51 (60.7)

403 (73.7)

   

Age (years)

median (IQR)

   

 At symptom onset

6 (4.2–9)

5.5 (3.6–9.3)

   

 At diagnosis

8 (5.4–10.6)

6.3 (4.2–9.8)

0.0424

  

 Time to diagnosis (months)

8.8 (2–23.6)

3.8 (1.9–8.9)

0.0011

1.029 [1.016–1.043]

< 0.0001

Ethnicity

n (%)

   

 Hispanic

12 (14.3)

83 (15.2)

   

Race

  

0.0047

  

 Caucasian

61 (72.6)

458 (83.7)

   

 African-American

19 (22.6)

63 (11.5)

 

2.264 [1.270–4.038]

0.0056

 Missing

4 (4.8)

26 (4.8)

   

JDM Category

n (%)

   

 Amyopathic

2 (2.4)

7 (1.3)

   

 Probable

61 (72.6)

429 (78.4)

   

 Definite

8 (9.5)

40 (7.3)

   

 Missing

13 (15.5)

71 (13)

   

Clinical features

n (%)

   

 Lipodystrophy

11 (13.1)

13 (2.4)

< 0.0001

5.993 [2.588–13.874]

< 0.0001

 Joint contractures

23 (27.4)

35 (6.4)

< 0.0001

5.343 [2.964–9.635]

< 0.0001

 Cutaneous ulceration

12 (13.5)

23 (4.2)

0.001

3.748 [1.787–7.862]

0.0005

 Gottron’s or Heliotrope

50 (59.5)

244 (44.6)

0.0176

1.754 [1.099–2.800]

0.0186

 Dysphagia or dysphonia

26 (31)

107 (19.6)

0.0178

  

 Small joint arthritis

25 (29.8)

115 (21.0)

0.041

  

 Malar or facial erythema

31 (36.9)

182 (33.3)

   

 V or Shawl sign

9 (10.7)

25 (4.6)

0.0377

2.410 [1.083–5.361]

0.0311

 Periungal Telangiectasia

40 (47.6)

225 (41.1)

   

 Cardiac involvement

4 (4.8)

10 (1.8)

   

 Gastrointestinal ulceration

3 (3.6)

7 (1.3)

   

 Interstitial lung disease

4 (4.8)

11 (2.0)

   

 Any organ involvementa

9 (10.7)

25 (4.6)

0.0333

2.506 [1.127–5.573]

0.0243

 Large joint arthritis

26 (31)

147 (26.9)

   

 Muscle enzyme elevation

74 (88.1)

481 (87.9)

   

 Severe muscle weakness

2 (2.4)

14 (2.6)

   
  1. aComposite outcome: includes cardiac, GI or lung involvement